Informed Prostate Cancer Patient Support

An 89Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer Patients | Journal of Nuclear Medicine

177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial | Journal of Nuclear Medicine

A Comprehensive Assessment of 68Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients | Journal of Nuclear Medicine

Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies | Prostate Cancer and Prostatic Diseases

Impact of positive surgical margin length and Gleason grade at the margin on oncologic outcomes in patients with nonorgan‐confined prostate cancer - Preisser - - The Prostate - Wiley Online Library

The effect of preoperative membranous urethral length on likelihood of postoperative urinary incontinence after robot-assisted radical prostatectomy | Prostate Cancer and Prostatic Diseases

Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies | Prostate Cancer and Prostatic Diseases

Compassionate Care: Reducing Anxiety - YouTube

Rochester Institute of Technology Scientists Secure NIH Grant to Study Virus as Prostate Cancer Treatment

A cancer stem cell population underlies a multi-lineage phenotype and drug resistance in prostate cancer | bioRxiv

Serum metabolomic analysis of men on a low-carbohydrate diet for biochemically recurrent prostate cancer reveals the potential role of ketogenesis to slow tumor growth: a secondary analysis of the CAPS2 diet trial | Prostate Cancer and Prostatic Diseases

Diptoindonesin G antagonizes AR signaling and enhances the efficacy of antiandrogen therapy in prostate cancer - Mao - - The Prostate - Wiley Online Library

Serum metabolomic analysis of men on a low-carbohydrate diet for biochemically recurrent prostate cancer reveals the potential role of ketogenesis to slow tumor growth: a secondary analysis of the CAPS2 diet trial | Prostate Cancer and Prostatic Diseases

Novartis Announces FDA Approval of Pluvicto as the First Targeted Radioligand Therapy for Advanced Prostate Cancer

FDA Approves First Targeted Radioligand Therapy for Metastatic Prostate Cancer | MedPage Today

Localized prostate cancer disparities in risk group at presentation and access to treatment for Hispanic men - Docwire News

Androgen receptor activity in T cells limits checkpoint blockade efficacy | Nature

Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer

Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer | Novartis

New Trials in Prostate Cancer: Could Your Patients Benefit?

ORIC Pharmaceuticals Discontinues Development of Lead Candidate Following Clinical Trial Failures

Local Failure after Prostate SBRT Predominantly Occurs in the PI-RADS 4 or 5 Dominant Intraprostatic Lesion - Docwire News

Comparison of Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging in Patients with Prostate Biopsy Indications - Docwire News

The impact of a fasting mimicking diet on the metabolic health of a prospective cohort of patients with prostate cancer: a pilot implementation study | Prostate Cancer and Prostatic Diseases : This pilot prospective study investigated the effect of a periodic fasting mimicking diet (FMD) on metabolic health factors in patients with Prostate Cancer (PC). There is a well-documented association between PC and metabolic health. Impaired metabolic health is a significant risk factor for the development of PC, and a metabolic syndrome can be induced by hormonal therapies commonly required for its management. (ClinicalTrials.gov Identifier: NCT04292041). We introduced a periodic 5-day FMD -low in calories, sugars, and proteins but high in unsaturated fats -to a cohort of PC patients and features of metabolic syndrome. 29/35 patients completed 3-monthly cycles of the 5-consecutive day packaged FMD. We compared the subjects’ baseline weight, abdominal circumference (AC), blood pressure (BP) and

The impact of a fasting mimicking diet on the metabolic health of a prospective cohort of patients with prostate cancer: a pilot implementation study | Prostate Cancer and Prostatic Diseases

Comparison of Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging in Patients with Prostate Biopsy Indications - Docwire News

Merck Halts KEYLYNK-010 Trial Evaluating Keytruda plus Lynparza for Metastatic Castration-Resistant Prostate Cancer Due to Insufficient Efficacy

Local Failure after Prostate SBRT Predominantly Occurs in the PI-RADS 4 or 5 Dominant Intraprostatic Lesion - Docwire News

Magnetic Seeds Used to Heat and Kill Cancer - Medical Design Briefs

Node Positive Prostate Cancer – Treatment and Survival — Cancer ABCs

Gene expression signature of castrate resistant prostate cancer | bioRxiv

Localized prostate cancer disparities in risk group at presentation and access to treatment for Hispanic men | Prostate Cancer and Prostatic Diseases : Despite great heterogeneity amongst Hispanic groups, prostate cancer studies often report Hispanic patients in aggregate. We sought to identify differences in prostate cancer risk group at presentation and treatment status among Hispanic subgroup populations. Patients with localized prostate adenocarcinoma diagnosed from 2004–2017 were identified in the National Cancer Database (NCDB) and disaggregated by racial subgroup and Hispanic country of origin. Ordinal logistic regression defined adjusted odds ratios (AORs) with 95% CI of (1) presenting at progressively higher risk group and (2) receiving treatment with intermediate-unfavorable or high-risk disease. In our sample (n = 895,087), Hispanic men had greater odds of presenting with higher-risk localized prostate cancer compared with non-Hispanic White men (AOR = 1.18 95% CI 1.16–1.21,

Association of plant-based diet index with prostate cancer risk | The American Journal of Clinical Nutrition | Oxford Academic

Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer | Prostate Cancer and Prostatic Diseases

[18F]-Labeled PARP-1 PET Imaging of PSMA Targeted Alpha Particle Radiotherapy Response | bioRxiv

More Metastatic Prostate Cancer; How Survivors Stay Healthy; Cancer's Medical Debt | MedPage Today

(1) An AI-derived digital pathology-based biomarker to predict the benefit of ADT in PC with validat... - YouTube

As Use of PSA Test Fell, Rate of Advanced Prostate Cancers Rose : Ever since routine prostate-specific antigen (PSA) screening tests have no longer been recommended, there has been a troubling rise in advanced prostate cancer cases in the United States, new research has found.

Serum thymidine kinase 1 concentration as a predictive biomarker in prostate cancer - Lundgren - - The Prostate - Wiley Online Library

Metastatic prostate cancer on the rise since decrease in cancer screenings -- ScienceDaily

177Lu‐PSMA radioligand therapy effectiveness in metastatic castration‐resistant prostate cancer: An updated systematic review and meta‐analysis - Sadaghiani - - The Prostate - Wiley Online Library

Clinical and pathological features associated with circulating tumor DNA content in real‐world patients with metastatic prostate cancer - Antonarakis - - The Prostate - Wiley Online Library

Prostate Cancer Patients to Reap the Benefits of “Seeds” Planted by NRG Oncology/RTOG 0526 - International Journal of Radiation Oncology, Biology, Physics

Merck to stop clinical trial testing Keytruda with AstraZeneca's Lynparza in prostate cancer patients - MarketWatch

Evaluation of selective bone scan staging in prostate cancer – external validation of current strategies and decision-curve analysis | Prostate Cancer and Prostatic Diseases

As Predicted: Jump in Metastatic Prostate Cancer Diagnoses

Which cancers are still diagnosed by standard prostate biopsy without an upfront multiparametric MRI? Results from a tertiary care, high volume centre - ScienceDirect

Dosimetric benefit of MR-guided online adaptive radiotherapy in different tumor entities: liver, lung, abdominal lymph nodes, pancreas and prostate | Radiation Oncology | Full Text

Assessment after focal therapy: what is the latest? : Current Opinion in Urology

Implications of DNA damage repair alterations for the manage... : Current Opinion in Urology

The role of novel imaging in prostate cancer focal therapy:... : Current Opinion in Urology

Optimized high-throughput screening of non-coding variants identified from genome-wide association studies | bioRxiv

Cancer-sniffing ants prove as accurate as dogs in detecting disease

Early prostate cancers can harbor aggressive tumor cells

Prostate cancer death prediction & Gleason score | CLEP

SATB1, genomic instability and Gleason grading constitute a novel risk score for prostate cancer | Scientific Reports

Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography - Docwire News

iPCa from prostate with benign biopsies | IJGM

Tumor Board Reviewing pT3N1M0 Locally Advanced Prostate Cancer - CASE 1

AUA 2021: State-of-the-art Lecture: Personalized Medicine in the Management of Prostate Cancer Across the Patient Care Continuum

How Prostate Cancer Is Treated

Prostate cancer: recognition and diagnosis - The Pharmaceutical Journal

Oncogenic gene fusions in nonneoplastic precursors as evidence that bacterial infection can initiate prostate cancer | PNAS

Use of PSMA PET Scans in Advanced Prostate Cancer

Some Men With PI-RADS 5 Lesions Can Forgo Systematic Prostate Biopsy - Renal and Urology News

Prostate cancer urine test identifies good prognosis patients

Cureus | Gallium-68 Prostate-Specific Membrane Antigen Positron Emission Tomography: A Practical Guide for Radiologists and Clinicians

MicroRNA dysregulation in prostate cancer | PGPM

Recent Advances in Systematic and Targeted Prostate Biopsies | RRU

Prostate Cancer Survival Rates | Prostate Cancer Foundation

Stage 4 Prostate Cancer Treatments and Prognosis

Prostate cancer: Symptoms, treatment, and causes

The Future of Prostate Cancer Care: Taking the Fight Early

Prostate cancer: Stages, treatment, and outlook

Prostate cancer surgery: Types, side effects, and outlook

Docetaxel in metastatic castration-resistant prostate cancer | OTT

Novartis 177Lu-PSMA-617 significantly improves overall

Updates in Immune Checkpoint Inhibitors for Prostate Cancer

How Prostate Cancer Is Diagnosed

A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND) | Prostate Cancer and Prostatic Diseases

Gleason score: What is it, results, and other measurements for prostate cancer

A Decision Analysis Approach Points to Better Diagnosis of Prostate Cancer  | Yale Insights

Multimodality Imaging of Prostate Cancer | Journal of Nuclear Medicine

Metastatic prostate cancer: Treatment and prognosis

Prostate nodule: Causes, changes, and diagnosis

Unfruitful: Eating More Produce Will Not Cure, Stop Prostate Cancer

18F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy | Journal of Nuclear Medicine

AUA 2020: Crossfire: Controversies in Urology: Prostate Cancer Active Surveillance Can Be Done with mpMRI and Biomarkers; Biopsies are No Longer Necessary

Prostate Cancer Immunotherapy Alone Is Not Enough - Renal and Urology News

An Expert Discussion on Gleason 6 (Grade Group 1) Prostate Cancer - Scott Eggener

Should men be concerned about prostate cancer?

Post-Operative Radiotherapy in Prostate Cancer – The State of the Data

A Systematic Review of Artificial Intelligence in Prostate Cancer | RRU

ASCO GU 2021: Efficacy of the PD-L1 Inhibitor Avelumab in Neuroendocrine or Aggressive Variant Prostate Cancer: Results From a Phase II, Single-Arm Study

Many Cancer Centers May Not Be Following PSA Screening Advice

Serendipity for the intervention of COVID-19 and prostatic adenocarcinoma (PaC) | Prostate Cancer and Prostatic Diseases

Diagnostic and prognostic significance of extracellular vesicles in prostate cancer drug resistance: A systematic review of the literature | Prostate Cancer and Prostatic Diseases

Long term genitourinary toxicity following curative intent intensity-modulated radiotherapy for prostate cancer: a systematic review and meta-analysis | Prostate Cancer and Prostatic Diseases

Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database - Beckmann - - The Prostate - Wiley Online Library

Quality of life after robotic‐assisted and laparoscopic radical prostatectomy: Results of a multicenter randomized controlled trial (LAP‐01) - Holze - - The Prostate - Wiley Online Library

New risk algorithm would improve screening for prostate cancer -- ScienceDaily

Long term genitourinary toxicity following curative intent intensity-modulated radiotherapy for prostate cancer: a systematic review and meta-analysis | Prostate Cancer and Prostatic Diseases

New ultrasound method as effective as MRI in diagnosing prostate cancer

The role of radiotherapy in oligometastatic hormone-sensitiv... : Current Opinion in Urology

Certain Types of Cancer May Increase the Risk of Developing Guillain-Barré

Focal prostate cancer therapy in the era of multiparametric MRI: a review of options and outcomes | Prostate Cancer and Prostatic Diseases

Liquid biomarkers for early detection of prostate cancer and summary of available data for their use in African-American men | Prostate Cancer and Prostatic Diseases

Hereditary cancer risk assessment and genetic testing in the community urology practice setting - Shore - - The Prostate - Wiley Online Library

(27) ESMO Expert Report on combination therapy in advanced prostate cancer @ ASCO GU 2022 - YouTube

Focal prostate cancer therapy in the era of multiparametric MRI: a review of options and outcomes | Prostate Cancer and Prostatic Diseases

Ultrasound scan can diagnose prostate cancer -- ScienceDaily

RADAR Guide: Standard Methods for Calculating Radiation Doses for Radiopharmaceuticals, Part 2—Data Analysis and Dosimetry | Journal of Nuclear Medicine

Androgen deprivation therapy for prostate cancer and the risk of thyroid diseases - Liu - - The Prostate - Wiley Online Library

Survival after radical prostatectomy versus radiation therapy in clinical node‐positive prostate cancer - Chierigo - - The Prostate - Wiley Online Library

Ultrasound scan can diagnose prostate cancer | EurekAlert!

The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation | Journal of Nuclear Medicine : Prostate-specific membrane antigen (PSMA) is a credentialed imaging and therapy (theranostic) target for the detection and treatment of prostate cancer. PSMA-targeted PET imaging and molecular radiotherapy are promising evolving technologies that will improve the outcomes of prostate cancer patients. In anticipation of this new era in prostate cancer theranostics, this article will review the history of PSMA from discovery through early- and late-stage clinical trials. Since 1993, the Prostate Cancer Foundation has funded critical and foundational PSMA research that established this theranostic revolution. The history and role of Prostate Cancer Foundation funding in this field will be discussed.

The Promise of Metastasis-Directed Therapy for Oligometastatic Prostate Cancer: Going Beneath the Surface with Molecular Imaging | Journal of Nuclear Medicine

177Lu-Prostate-Specific Membrane Antigen Ligand After 223Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience | Journal of Nuclear Medicine